Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agnieszka K Witkiewicz

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
Oncotarget|August 27, 2016
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancerErik S Knudsen, Agnieszka K Witkiewicz
Cancer Biology & Therapy|August 6, 2010
CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancersJonathan R Brody, Agnieszka K Witkiewicz
Aging|September 2, 2017
The transcriptome of CDK4/6 inhibitionErik S Knudsen, Agnieszka K Witkiewicz
Cell Cycle (Georgetown, Tex.)|April 20, 2011
RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapyAgnieszka K Witkiewicz, Erik S Knudsen
Breast Cancer Research : BCR|September 17, 2014
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsAgnieszka K Witkiewicz, Erik S Knudsen
Trends in Cancer|March 18, 2017
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination StrategiesErik S Knudsen, Agnieszka K Witkiewicz
Genes & Cancer|September 16, 2014
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer modelsAgnieszka K Witkiewicz, Derek Cox, Erik S Knudsen
Acta Cytologica|April 16, 2009
Expression of K homology domain containing protein (KOC) in pancreatic cytology with corresponding histologyAdam D Toll, Agnieszka K Witkiewicz, Marluce Bibbo
Nature Reviews. Drug Discovery|April 27, 2026
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyondErik S Knudsen, Agnieszka K Witkiewicz, Sheheryar Kabraji
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2014
Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkersAgnieszka K Witkiewicz, Uthra Balaji, Erik S Knudsen
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
Oncotarget|August 27, 2016
Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancerErik S Knudsen, Agnieszka K Witkiewicz
Cancer Biology & Therapy|August 6, 2010
CXCR4 signaling identifies a role for IFT2 in ER-negative breast cancersJonathan R Brody, Agnieszka K Witkiewicz
Aging|September 2, 2017
The transcriptome of CDK4/6 inhibitionErik S Knudsen, Agnieszka K Witkiewicz
Cell Cycle (Georgetown, Tex.)|April 20, 2011
RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapyAgnieszka K Witkiewicz, Erik S Knudsen
Breast Cancer Research : BCR|September 17, 2014
Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsAgnieszka K Witkiewicz, Erik S Knudsen
Trends in Cancer|March 18, 2017
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination StrategiesErik S Knudsen, Agnieszka K Witkiewicz
Genes & Cancer|September 16, 2014
CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer modelsAgnieszka K Witkiewicz, Derek Cox, Erik S Knudsen
Acta Cytologica|April 16, 2009
Expression of K homology domain containing protein (KOC) in pancreatic cytology with corresponding histologyAdam D Toll, Agnieszka K Witkiewicz, Marluce Bibbo
Nature Reviews. Drug Discovery|April 27, 2026
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyondErik S Knudsen, Agnieszka K Witkiewicz, Sheheryar Kabraji
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2014
Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkersAgnieszka K Witkiewicz, Uthra Balaji, Erik S Knudsen
Pageof 17